January 02, 2026 a 07:31 am
MRK: Dividend Analysis - Merck & Co., Inc.
Merck & Co., Inc., a leading player in the pharmaceutical sector, has shown a steadfast commitment to rewarding its shareholders through consistent dividends. With over five decades of dividend history and a moderate yield, Merck stands as a reliable staple for income-focused investors. However, potential investors should weigh the historical stability against the recent payout ratios, which suggest conscientious financial management.
Overview 📊
Merck's dividend profile is robust, underpinned by its long-standing consistency in payments. The company's ability to sustain a dividend yield of 3.27% reflects its strong cash flow generation capabilities.
| Sector | Dividend Yield | Current Dividend per Share | Dividend History | Last Cut or Suspension |
|---|---|---|---|---|
| Pharmaceuticals | 3.27% | 3.10 USD | 56 years | 2004 |
Dividend History 🗣️
The dividend history of Merck is indicative of its commitment to returning value to shareholders. The continuous dividend payments over the past 56 years underscore its resilience and cash flow stability, crucial for investors seeking predictable income streams.
| Year | Dividend Per Share (USD) |
|---|---|
| 2025 | 3.28 |
| 2024 | 3.12 |
| 2023 | 2.96 |
| 2022 | 2.80 |
| 2021 | 2.61 |
Dividend Growth 📈
Merck has demonstrated steady dividend growth, indicative of its strong financial health and ability to enhance shareholder value over time.
| Time | Growth |
|---|---|
| 3 years | 5.42% |
| 5 years | 6.75% |
The average dividend growth is 6.75% over 5 years. This shows moderate but steady dividend growth, reflecting ongoing financial discipline and operational success.
Payout Ratio 🧮
Payout ratios provide insight into the sustainability of dividend payments and the company's allocation of earnings.
| Key Figure | Ratio |
|---|---|
| EPS-based | 40.64% |
| Free Cash Flow-based | 59.64% |
An EPS-based payout of 40.64% and an FCF-based ratio of 59.64% suggest a balanced approach to dividend payments, ensuring coverage from both profits and cash flows.
Cashflow & Capital Efficiency 💰
Analyzing Merck's cash flow provides key insights into its operational efficiency and financial health.
| Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Free Cash Flow Yield | 7.18% | 3.22% | 5.24% |
| Earnings Yield | 6.80% | 0.13% | 5.17% |
| CAPEX to Operating Cash Flow | 15.71% | 29.70% | 22.98% |
| Stock-based Compensation to Revenue | 1.19% | 1.07% | 0.91% |
| Free Cash Flow / Operating Cash Flow Ratio | 84.29% | 70.30% | 77.02% |
The stability of Merck's cash flow, along with its prudent capital management, reflects positively on its capital efficiency and ability to maintain dividend payments.
Balance Sheet & Leverage Analysis 📋
Merck's leverage ratios highlight its financial resilience and prudent debt management.
| Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt-to-Equity | 0.83 | 0.97 | 0.70 |
| Debt-to-Assets | 0.33 | 0.34 | 0.29 |
| Debt-to-Capital | 0.45 | 0.49 | 0.41 |
| Net Debt to EBITDA | 0.97 | 4.26 | 0.91 |
| Current Ratio | 1.36 | 1.25 | 1.47 |
| Quick Ratio | 1.15 | 1.00 | 1.23 |
| Financial Leverage | 2.53 | 2.84 | 2.37 |
Merck maintains a solid balance sheet, indicative of its strong financial footing and capacity to manage obligations while pursuing growth opportunities.
Fundamental Strength & Profitability ✅
Merck’s profitability metrics reflect efficient operations and robust underlying fundamentals.
| Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Return on Equity | 36.96% | 0.97% | 31.57% |
| Return on Assets | 14.62% | 0.34% | 13.30% |
| Net Margin | 26.68% | 0.61% | 24.49% |
| EBIT Margin | 33.05% | 5.05% | 29.36% |
| Research & Development to Revenue | 27.95% | 50.79% | 22.85% |
Merck's strong margins and elevated returns on equity signify superior profitability potential, driving higher investment value over the long term.
Price Development 📉
Dividend Scoring System 🏆
| Criteria | Score (1-5) | Score Bar |
|---|---|---|
| Dividend Yield | 4 | |
| Dividend Stability | 5 | |
| Dividend Growth | 3 | |
| Payout Ratio | 4 | |
| Financial Stability | 5 | |
| Dividend Continuity | 5 | |
| Cashflow Coverage | 4 | |
| Balance Sheet Quality | 5 |
Overall Score: 35/40
Rating 🏅
Merck & Co., Inc. is a solid choice for dividend investors seeking consistent yields and strong financial health. With a stable dividend history and strong balance sheet metrics, Merck is well-positioned to continue delivering value. A cautious optimistic rating, considering its strategic initiatives and sector dynamics, is recommended.